Advertisement

European Journal of Nuclear Medicine

, Volume 8, Issue 12, pp 541–545 | Cite as

Post-operative diagnosis and therapy of thyroid carcinoma by nuclear medicine

  • H. Hundeshagen
Review
  • 19 Downloads

Keywords

Public Health Carcinoma Nuclear Medicine Thyroid Carcinoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Beierwaltes HW (1978) The treatment of thyroid carcinoma with radioactive iodine. Semin Nucl Med 8:79–94Google Scholar
  2. 2.
    Biersack HJ, Winkler K (1982) Neue Aspekte in Diagnostik und Therapie der Schilddrüsenkarzinome. Schattauer Verlag, StuttgartGoogle Scholar
  3. 3.
    Blahd WH (1979) Treatment of malignant thyroid disease. Semin Nucl Med 9:95–99Google Scholar
  4. 4.
    Bonte FJ, McConnell RW (1973) Pulmonary metastases from differentiated thyroid carcinoma demonstrable only by nuclear imaging. Radiology 107:585–590Google Scholar
  5. 5.
    Börner W, Reiners C (1980) Die Aufgaben des Nuclearmediziners in der Therapie des Schilddrüsen Carzinoms. Med Klin 75:80–87Google Scholar
  6. 6.
    Brinker H, Hansen HS, Andersen AP (1973) Induction of leukaemia by 131-J-treatment of thyroid-carcinoma. Br J Cancer 28:232–237Google Scholar
  7. 7.
    Casara D, Zorat PL, Busnardo B, Girelli ME (1981) Pulmonary metastases from differentiated thyroid carcinoma detected only by radionuclide imaging. Br J Radiol 54:362–363Google Scholar
  8. 8.
    Catz B, Starr P (1956) Cancer of the thyroid with metastases to the lung. JAMA 160:1046–1047Google Scholar
  9. 9.
    Choné B (1980) Vergleichende hämatologische Verlaufsuntersuchungen nach kumulativer 131-J-Therapie von Schilddrüsenmalignomen. Therapiewoche 30:3355–3366Google Scholar
  10. 10.
    Glanzmann CH, Horst W (1978) Therapie des metastasierenden Schilddrüsenkarzinoms mit 131-J. Strahlentherapie 155:223–229Google Scholar
  11. 11.
    Glanzmann CH, Horst W (1979) Behandlung und Prognose des follikulären und papillären Schilddrüsenkarzinoms. Strahlentherapie 155:515–528Google Scholar
  12. 12.
    Gottleib JA, Hill CS, Jr. (1974) Chemotherapy of thyroid cancer with adriamycin. N Engl J Med 290:193–197Google Scholar
  13. 13.
    Gottleib JA, Hill CS Jr, Ibanez MJ (1972) Chemotherapy of thyroid cancer. An evaluation of experience with 37 patients. Cancer 30:848–853Google Scholar
  14. 14.
    Jänsch A, Heinz HG, Hast B (1981) Serum-Thyreoglobulin (S-hTG): Ein Tumormarker bei Patienten mit differenziertem Schilddrüsenkarzinom. Strahlentherapie 157:381–392Google Scholar
  15. 15.
    Kuni CH C, Klingenschmith WC (1980) Failure of low doses 131-J to oblate residual thyroid tissue following surgery of thyroid cancer. Radiology 137:773–774Google Scholar
  16. 16.
    Mazzaferri EL, Young RL (1981) Papillary thyroid carcinoma: A 10 year follow-up report of the impact of therapy in 576 patients. Am J Med 70:511–518Google Scholar
  17. 17.
    Mazzaferri EL, Young RL, Oertel TW (1977) Papillary thyroid carcinoma the impact of therapy in 576 patients. Medicine 56:171–196Google Scholar
  18. 18.
    Nemec J, Rohling S, Zamravil V (1979) Comparison of the distribution of diagnostic and thyroablating J-131 in the evaluation of differentiated thyroid cancers. J Nucl Med 20:92–97Google Scholar
  19. 19.
    Riccabona G (1979) Strahlentherapie und nuklearmedizinische Maßnahmen bei Malignomen der Schilddrüse. Therapiewoche 29:3448–3462Google Scholar
  20. 20.
    Schad K, Mariß P, Junker D, Hundeshagen H (1979) Schilddrüsen-und Restkörperstrahlenexposition bei Radiojodtherapie benigner Schilddrüsenerkrankungen. Nuklearmedizin, F.K. Schattauer-Verlag: 730–734Google Scholar
  21. 21.
    Schimaoka K, Sako K, Friedman M, Baksh B, Rao U (1980) Carcinoma of the Thyroid Gland. Int Adv Surg Oncol 3:111–155Google Scholar
  22. 22.
    Siddiqui AR, Edmondson JE, Wellman HN (1981) Feasibility of low doses of J-131 for thyroid ablation in postsurgical patients with thyroid carcinoma. Clin Nucl Med 6:158–161Google Scholar
  23. 23.
    Steuer KT (1981) Zur Prognose und Verlaufskontrolle des Carcinoms; Inaugural-Dissertation, Julius-Maximilians Universität WürzburgGoogle Scholar
  24. 24.
    Thomas SR, Maxon HR, Kereiakes JG, Saenger EL (1977) Quantitative external counting techniques enabling improved diagnostic and therapeutic decisions in patients with well-differentiated thyroid cancer. Radiology 122:731–737Google Scholar
  25. 25.
    Tong Fui SC NG, Hoffenberg R, Maisey MN, Block EG (1979) Serum thyroglobulin concentrations and whole-body radioiodine scan in follow-up of differentiated thyroid cancer after thyroid ablation. Br Med J 2:298–300Google Scholar
  26. 26.
    Varma VM, Beierwaltes HW, Nofal MM (1970) Treatment of thyroid cancer. Death rates after surgery and after surgery followed by sodium iodine I-131. JAMA 214:1437–1442Google Scholar
  27. 27.
    Waxman A, Ramanna L, Chapman N, Capman D, Brachman M, Tanasescu D, Bergman D, Catz B, Braunstein G (1981) The significance of I 131 scan dose in patients with thyroid cancer, determination of ablation. J Nucl Med 22:861–865PubMedGoogle Scholar

Copyright information

© Springer-Verlag 1983

Authors and Affiliations

  • H. Hundeshagen
    • 1
  1. 1.Abteilung für Nuklearmedizin und spezielle Biophysik, Radiologisches ZentrumMedizinische Hochschule HannoverHannoverFederal Republic of Germany

Personalised recommendations